Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
2.050
-0.030 (-1.44%)
At close: Sep 12, 2025, 4:00 PM EDT
2.100
+0.050 (2.44%)
After-hours: Sep 12, 2025, 7:41 PM EDT
Cardiff Oncology Stock Forecast
Stock Price Forecast
The 5 analysts that cover Cardiff Oncology stock have a consensus rating of "Strong Buy" and an average price target of $11.1, which forecasts a 441.46% increase in the stock price over the next year. The lowest target is $3.50 and the highest is $19.
Price Target: $11.1 (+441.46%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 6, 2025.
Analyst Ratings
The average analyst rating for Cardiff Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $10 | Strong Buy | Maintains | $18 → $10 | +387.80% | Aug 6, 2025 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $19 | Strong Buy | Initiates | $19 | +826.83% | Jul 8, 2025 |
| Jefferies | Jefferies | Hold Initiates $3.5 | Hold | Initiates | $3.5 | +70.73% | Jun 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $17 → $18 | Strong Buy | Maintains | $17 → $18 | +778.05% | May 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13 → $17 | Strong Buy | Maintains | $13 → $17 | +729.27% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
443.70K
from 683.00K
Decreased by -35.04%
Revenue Next Year
335.33K
from 443.70K
Decreased by -24.43%
EPS This Year
-0.85
from -0.95
EPS Next Year
-0.87
from -0.85
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 556,500 | 630,000 | |||
| Avg | 443,700 | 335,325 | |||
| Low | 225,400 | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -18.5% | 42.0% | |||
| Avg | -35.0% | -24.4% | |||
| Low | -67.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.82 | -0.68 | |||
| Avg | -0.85 | -0.87 | |||
| Low | -0.96 | -1.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.